Formulación en desarrollo
Fluxapyroxad 5% + Epoxiconazole 5% + Pyraclostrobin 8.1% EC
AZOXISTROBIN 30% + BENZOVINDIFLUPIR 15% WG
Benzovindiflupyr 4% + Propiconazole 25% EC
Topramezone 336 g/L SC
